Poor
Not Aligned
Patient Risk:
Moderate
Summary
Only the FDA boxed warning/indications-related statements provided in the prompt can be assessed; most liver-enzyme and monitoring claims are not supported or contradicted by the supplied label excerpts, and the use-history/approval-year claims cannot be verified from the provided label sections.
Category Scores
Accurate Statements
Elevated liver enzyme levels can indicate liver damage or disease.
Not supported or contradicted by the supplied FDA label excerpts provided.
Unsupported Statements
Tigecycline can affect liver enzymes over time.
No support in the provided FDA label excerpts (only all-cause mortality/limitations-of-use text was supplied).
Tigecycline can cause elevated ALT levels.
No support in the provided FDA label excerpts.
Tigecycline can cause elevated AST levels.
No support in the provided FDA label excerpts.
Tigecycline can cause elevated ALP levels.
No support in the provided FDA label excerpts.
Tigecycline can cause elevated GGT levels.
No support in the provided FDA label excerpts.
Tigecycline can cause elevated bilirubin levels.
No support in the provided FDA label excerpts.
The exact mechanism of tigecycline's impact on liver enzymes is not fully understood.
No mechanistic discussion related to liver enzymes is present in the supplied excerpts.
Research suggests tigecycline may cause liver enzyme elevations through inhibition of protein synthesis in the liver.
Not supported by the supplied FDA label excerpts.
Research suggests tigecycline may cause liver enzyme elevations through increased oxidative stress in the liver.
Not supported by the supplied FDA label excerpts.
Research suggests tigecycline may cause liver enzyme elevations through disruption of bile flow.
Not supported by the supplied FDA label excerpts.
Elevated liver enzyme levels can indicate liver failure.
Not supported by the supplied FDA label excerpts.
Elevated bilirubin levels can indicate biliary obstruction.
Not supported by the supplied FDA label excerpts.
Biliary obstruction can lead to complications including liver failure and sepsis.
Not supported by the supplied FDA label excerpts.
Patients receiving tigecycline should have liver enzymes monitored regularly.
No monitoring recommendation for liver enzymes is included in the supplied FDA label excerpts.
Liver enzymes should be monitored ideally every 2-3 days in patients receiving tigecycline.
No monitoring frequency is included in the supplied FDA label excerpts.
Tigecycline can cause liver damage, including elevated liver enzyme levels and liver failure.
No liver-damage/liver-failure statements appear in the supplied FDA label excerpts.
Tigecycline should be used with caution in patients with pre-existing liver disease.
No caution statement for pre-existing liver disease is included in the supplied FDA label excerpts.
Treatment options for liver enzyme elevations caused by tigecycline include discontinuing the medication.
No treatment guidance for liver enzyme elevations is included in the supplied FDA label excerpts.
Treatment options for liver enzyme elevations caused by tigecycline include administering supportive care.
No treatment guidance is included in the supplied FDA label excerpts.
Treatment options for liver enzyme elevations caused by tigecycline include monitoring liver enzymes regularly.
No treatment guidance/monitoring recommendation is included in the supplied FDA label excerpts.
Tigecycline was approved by the FDA in 2005 for complicated skin and skin structure infections (cSSSI).
No approval year/approval-history information for cSSSI is present in the supplied FDA label excerpts.
Tigecycline was approved by the FDA in 2005 for intra-abdominal infections (IAI).
No approval year/approval-history information for cIAI/IAI is present in the supplied FDA label excerpts.
Tigecycline was approved by the FDA in 2005 for community-acquired bacterial pneumonia (CABP).
No approval year/approval-history information for CABP is present in the supplied FDA label excerpts.
Contradictions
Important Omissions
The response does not include the boxed warning’s key content (increased all-cause mortality; cause not established; reserve for situations when alternative treatments are not suitable).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response makes multiple liver-enzyme monitoring/treatment recommendations that are not supported by the supplied FDA label excerpts, which could lead to reliance on unverified safety guidance. The supplied label content provided in the prompt concerns all-cause mortality, which is not addressed by the listed liver-enzyme claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims (liver enzyme effects, monitoring frequency, and management steps) are not supported by the FDA label excerpts provided in the prompt. Approval-year statements also cannot be verified from the supplied sections.
Suggested Improvement
Limit claims to information explicitly present in the provided label excerpts (boxed warning/all-cause mortality, limitations of use/indications as referenced, and trial mortality imbalance). Remove or qualify liver-enzyme and monitoring statements unless the corresponding label sections (e.g., Warnings/Precautions for hepatic effects) are provided and can be cited.